In the Chinese pharmaceutical industry, there were 26 M&A deals announced in Q2 2023, worth a total value of $268.6m, according to GlobalData’s Deals Database. The $33.1m minority acquisition of gansu longshenrongfa pharmaceutical industry by gansu xinglong capital management was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in China decreased by 76% in Q2 2023 compared with the previous quarter’s total of $1.1bn and fell by 64% as compared to Q2 2022. Related deal volume decreased by 28% in Q2 2023 versus the previous quarter and was 271% higher than in Q2 2022.
The top-ranked legal advisorss supporting these M&A deals in China Q2 2023 were Beijing Deheng; DeHeng Law Offices; Dorsey & Whitney with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.